PARP1 and heart failure: Furthermore, we discuss novel druggable targets for AF and highlight future directions for clinical trials with drugs directed at DNA damage-PARP1-NAD+ axis with the ultimate aim to preserve quality of life and to attenuate severe complications such as heart failure or stroke in patients with AF.